公开(公告)号：US20240226342A1

公开(公告)日：2024-07-11

申请号：US18529171

申请日：2023-12-05

Applicant: Vijay Sharma ,  Lakshminarayana Satham ,  Jothilingam Sivapackiam

Inventor： Vijay Sharma ,  Lakshminarayana Satham ,  Jothilingam Sivapackiam

IPC: A61K51/04

CPC classification number: A61K51/0459

Abstract: The present disclosure provides compositions and methods for reactive oxygen species imaging agents. Compositions include a reactive oxygen species (ROS) imaging agent according to any one of Formulas (I-VI)a and (I-VII)b. Methods of detecting ROS in a subject include administering to the subject an effective amount of a composition comprising a reactive oxygen species (ROS) imaging agent according to any one of Formulas (I-VI)a and (I-VII)b, and exposing the subject to an imaging modality such as PET or CT. Administering the composition comprising the ROS imaging agent results in penetration of the ROS imaging agent into a membrane, oxidation of the ROS imaging 10 agent by ROS, and trapping of the ROS imaging agent in a cell membrane and intracellular compartments.

公开(公告)号：US20240216553A1

公开(公告)日：2024-07-04

申请号：US18400969

申请日：2023-12-29

Applicant: Washington University

Inventor： Yongjian Liu ,  Xiuli Zhang ,  Gyu Seong Heo

IPC: A61K51/08 ,  A61K51/04

CPC classification number: A61K51/088 ,  A61K51/0482 ,  A61K2121/00 ,  A61K2123/00

Abstract: Among the various aspects of the present disclosure is the provision of compositions of CD163 targeting and theranostic agents and methods for use in detecting, monitoring, and evaluating CD163 associated diseases, disorders, and conditions.

公开(公告)号：US20240199722A1

公开(公告)日：2024-06-20

申请号：US18285877

申请日：2022-04-07

Applicant: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION

Inventor： Yun Sang LEE ,  Seung Hyeok SEOK ,  Hongyoon CHOI ,  Hyung-jun IM ,  Ji Yong PARK ,  Minseok SUH ,  Hyewon CHUNG

IPC: C07K14/765 ,  A61K9/51 ,  A61K31/663 ,  A61K49/00 ,  A61K51/04 ,  A61K51/12 ,  A61P35/04

CPC classification number: C07K14/765 ,  A61K9/51 ,  A61K31/663 ,  A61K49/005 ,  A61K51/04 ,  A61K51/12 ,  A61P35/04

Abstract: A nanoplatform for targeting macrophages is obtained by a click chemistry reaction between albumin conjugated with an aizde (N3) or cyclooctyne functional group and a transmitter conjugated with an azide (N3) or cyclooctyne functional group, wherein the transmitter comprises a mannosyl group or a galactosyl group, and when the albumin is conjugated with the azide functional group, the transmitter is conjugated with the cyclooctyne functional group while, when the albumin is conjugated with the cyclooctyne functional group, the transmitter is conjugated with the azide functional group.

公开(公告)号：US20240197927A1

公开(公告)日：2024-06-20

申请号：US18541604

申请日：2023-12-15

Applicant: Fusion Pharmaceuticals Inc.

Inventor： Diane-Charlotte Imbs ,  Elodie Lewkowicz ,  Alexander McEwan ,  Thomas Rohban ,  Sylvie Rolland ,  Daniel Stevens ,  John R. Forbes

IPC: A61K51/04 ,  A61K31/7068 ,  A61K47/64 ,  A61P35/00

CPC classification number: A61K51/0482 ,  A61K31/7068 ,  A61K47/643 ,  A61P35/00

Abstract: The present invention relates to a combination comprising a neurotensin receptor binding compound, gemcitabine and nab-paclitaxel for use for the treatment of a neurotensin receptor overexpressing tumour in a subject.

公开(公告)号：US12006302B2

公开(公告)日：2024-06-11

申请号：US17450212

申请日：2021-10-07

Applicant: Janssen Pharmaceutica NV

Inventor： José Ignacio Andrés-Gil ,  Guy Maurits R. Bormans ,  Lieven Denis Herwig Declercq ,  Katleen Fierens ,  Joseph Elisabeth Leenaerts ,  Diederik Willem Elisabeth Moechars ,  Frederik Jan Rita Rombouts ,  Hartmuth Kolb ,  Wei Zhang

IPC: C07D401/12 ,  A61K51/04 ,  C07B59/00

CPC classification number: C07D401/12 ,  A61K51/0455 ,  C07B59/002 ,  A61K2123/00

Abstract: The present invention relates to novel, selective radiolabelled tau ligands which are useful for imaging and quantifying tau aggregates, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue or a subject, in vitro or in vivo, and to precursors of said compounds.

公开(公告)号：US20240181092A1

公开(公告)日：2024-06-06

申请号：US18552760

申请日：2022-04-01

Applicant: NOVARTIS AG

Inventor： Ana CATAFAU ,  Elisabet PARERA PIELLA ,  Beilei HE ,  Euloge KPAMEGAN

IPC: A61K51/04 ,  A61K51/12

CPC classification number: A61K51/0402 ,  A61K51/0497 ,  A61K51/121

Abstract: The present disclosure relates to the field of diagnostic methods, and more particularly prostate cancer imaging. In particular, the disclosure relates to a radiopharmaceutical PSMA-binding compound for use in determining the presence and/or localization of PSMA-positive tumors in a subject in need thereof, wherein said subject has been diagnosed with biochemical recurrence, particularly after radical prostatectomy or radiotherapy, and wherein said radiopharmaceutical compound is the compound of formula (III).

公开(公告)号：US20240174608A1

公开(公告)日：2024-05-30

申请号：US18279162

申请日：2022-03-11

Applicant: The General Hospital Corporation

Inventor： Changning Wang ,  Yulong Xu ,  Can Zhang ,  Rudolph E. Tanzi

IPC: C07D209/88 ,  A61K51/04 ,  C07B59/00

CPC classification number: C07D209/88 ,  A61K51/0446 ,  C07B59/002 ,  A61K2123/00 ,  C07B2200/05

Abstract: The present application provides radiolabeled tetrahydrocarbazole compounds that can be used as positron emission tomography imaging probes. Pharmaceutical compositions and methods of using these compounds for diagnosis and monitoring treatment of neurodegenerative diseases (such as Alzheimer's disease) are also provided.

公开(公告)号：US20240165276A1

公开(公告)日：2024-05-23

申请号：US17768660

申请日：2020-10-15

Applicant: KARIN & STEN MORTSTEDT CBD SOLUTIONS AB

Inventor： Daniel Dungan Sohn

IPC: A61K51/04 ,  A61P25/28 ,  C07D401/14 ,  C07D417/14

CPC classification number: A61K51/0455 ,  A61P25/28 ,  C07D401/14 ,  C07D417/14

Abstract: The present invention provides a compound of formula (I) and compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt, ester, amide or carbamate thereof, or a salt of such an ester, amide or carbamate. The present invention also provides a compound of formula (X) and compositions comprising a compound of formula (X) or a pharmaceutically acceptable salt, ester, amide or carbamate thereof, or a salt of such an ester, amide or carbamate. The present invention further provides uses of the compounds of formula (I) and (X) and compositions comprising compounds of formula (I) and (X), including the use of such compounds and compositions for the diagnosis and treatment of neurodegenerative diseases, and especially tauopathies such as Alzheimer's disease.

公开(公告)号：US11986541B2

公开(公告)日：2024-05-21

申请号：US18232013

申请日：2023-08-09

Applicant: Vector Vitale IP LLC

Inventor： Peter Novak ,  Max Temnik ,  Oleksandr Balakin

IPC: A61K51/04 ,  A61K31/164 ,  A61K33/30 ,  A61P35/00

CPC classification number: A61K51/0476 ,  A61K31/164 ,  A61K33/30 ,  A61P35/00

Abstract: A method for treating melanoma or preventing the development of melanoma comprising administration of a composition comprising 64Zne(Asp)2 in a therapeutically effective amount. Such administration may be via injection such as intratumoral and/or intravenous injection and may be once a day or more than once a day. A composition for the treatment of or prevention of melanoma comprising 64Zne(Asp)2 in a therapeutically effective amount. The composition may be a liquid suitable for injection.

公开(公告)号：US11952368B2

公开(公告)日：2024-04-09

申请号：US17956727

申请日：2022-09-29

Applicant: XIAMEN UNIVERSITY

Inventor： Haojun Chen ,  Liang Zhao ,  Qin Lin ,  Kaili Fu ,  Yizhen Pang ,  Zhide Guo ,  Jianyang Fang ,  Long Sun ,  Hua Wu

IPC: C07D401/14 ,  A61K51/04

CPC classification number: C07D401/14 ,  A61K51/0482

Abstract: Provided are a fibroblast activation protein inhibitor (FAPI) dimer compound, an FAPI dimer-based positron emission tomography (PET) imaging agent for tumor diagnosis, and a preparation method and use thereof. An amphiphilic polyethylene glycol (PEG) chain and a dimerized structure of FAPI in the FAPI dimer compound with a structure shown in formula I can improve the in vivo kinetic properties of the compound and prolong a residence time of the compound in a tumor, thereby improving the uptake and imaging effects in the tumor. The accurate tumor diagnosis can be achieved by labeling the FAPI dimer compound with a diagnostic nuclide (68Ga), which has promising application prospects in PET imaging for diagnosis and in the preparation of a therapeutic nuclide (such as 177Lu or 90Y)-labeled drug for treating a FAP-α-expressing tumor.